Redcliffe Labs Raises $42M in Series C Funding Led by IFU

Redcliffe Labs, an omnichannel diagnostics provider, has secured $42 million in its Series C funding round, led by Denmark-based IFU, which contributed $20 million. Existing investor LeapFrog added $15 million, while the rest of the funds came from HealthQuad and Spark Growth Ventures.

This new investment follows the company’s previous rounds, including a $61 million Series B in May 2022 and $10 million Series A in April 2021. Other key investors include Schroders, LC Nueva, Chiratae Ventures, and Alkemi Venture Partners.

The fresh capital will be utilized to bolster Redcliffe’s expansion, particularly in Tier II and III cities across India. The company plans to increase its network by opening more labs, collection centers, and expanding its home collection services.

Redcliffe has been pursuing growth through strategic acquisitions in North-Western India and is focused on further expanding PAN-India through partnerships and acquisitions.

The company has strengthened its leadership team with the addition of Ankur Shah, former Chief Finance and Strategy Officer at Careem, as an independent director, and Alka Saxena, previously with Dr. Lal PathLabs, as CFO.

Redcliffe currently operates in over 220 cities in India with a network of 80 labs, 2,000+ collection centers, and home services. The firm claims to have served more than 7 million patients across tier I, II, and III cities.

Financially, Redcliffe’s operating revenue grew 2.6 times to ₹347 crore in FY23, up from ₹130 crore in FY22. However, the company’s losses increased fivefold to ₹345.6 crore, compared to ₹67.7 crore in the previous fiscal year.

Redcliffe Labs faces competition from PharmEasy-owned Thyrocare, Healthians, 1mg, and Dr. Lal PathLabs as it continues to grow its market share in India’s diagnostics sector.